Home / Market News / $BMY
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Bristol Myers Squibb and SystImmune Announce Positive Phase 3 Results for Izalontamab Brengitecan in NSCLC

Oct 26, 2026, 10:34 AM UTC · Primary ticker $BMY

Bristol Myers Squibb announced positive Phase 3 results for its drug izalontamab brengitecan, showing it doubled progression-free survival in NSCLC patients. This is a significant development for the company's oncology pipeline and could lead to a new treatment option for a difficult-to-treat cancer.

Bristol Myers Squibb and SystImmune announced positive interim Phase 3 results for izalontamab brengitecan, an antibody-drug conjugate, in previously-treated EGFR-mutated non-small cell lung cancer. The drug doubled median progression-free survival compared to chemotherapy, indicating a significant clinical benefit. This is a major positive for Bristol Myers Squibb, validating its investment in oncology and potentially adding a blockbuster drug to its portfolio. For traders, this represents a short-term opportunity for BMY stock appreciation due to increased confidence in its pipeline, and a long-term opportunity as the drug progresses towards approval and market entry, addressing a significant unmet medical need. The key risk would be any future regulatory hurdles or unexpected safety concerns.

$BMY positive Successful Phase 3 trial results for key oncology asset.
$SYST positive Co-developer of successful drug candidate.
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.